U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Endogenous Cushing Syndrome

MedGen UID:
1762723
•Concept ID:
C5419159
•
Disease or Syndrome

Definition

The reemergence of endogenous Cushing syndrome after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Endogenous Cushing Syndrome

Professional guidelines

PubMed

Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
Perosevic M, Tritos NA
Drug Des Devel Ther 2023;17:1303-1312. Epub 2023 Apr 27 doi: 10.2147/DDDT.S315359. PMID: 37143705Free PMC Article
Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome.
He X, Findling JW, Auchus RJ
Pituitary 2022 Jun;25(3):393-403. Epub 2022 Apr 26 doi: 10.1007/s11102-022-01218-y. PMID: 35471718Free PMC Article
Medical Management of Cushing's Syndrome: Current and Emerging Treatments.
Hinojosa-Amaya JM, Cuevas-Ramos D, Fleseriu M
Drugs 2019 Jun;79(9):935-956. doi: 10.1007/s40265-019-01128-7. PMID: 31098899

Recent clinical studies

Etiology

Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
Perosevic M, Tritos NA
Drug Des Devel Ther 2023;17:1303-1312. Epub 2023 Apr 27 doi: 10.2147/DDDT.S315359. PMID: 37143705Free PMC Article
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK; LINC 3 investigators
Lancet Diabetes Endocrinol 2020 Sep;8(9):748-761. Epub 2020 Jul 27 doi: 10.1016/S2213-8587(20)30240-0. PMID: 32730798
Medical Management of Cushing's Syndrome: Current and Emerging Treatments.
Hinojosa-Amaya JM, Cuevas-Ramos D, Fleseriu M
Drugs 2019 Jun;79(9):935-956. doi: 10.1007/s40265-019-01128-7. PMID: 31098899
Mortality in Patients with Endogenous Cushing's Syndrome.
Javanmard P, Duan D, Geer EB
Endocrinol Metab Clin North Am 2018 Jun;47(2):313-333. doi: 10.1016/j.ecl.2018.02.005. PMID: 29754634
Cushing's disease: the burden of illness.
Pivonello R, De Martino MC, De Leo M, Simeoli C, Colao A
Endocrine 2017 Apr;56(1):10-18. Epub 2016 May 17 doi: 10.1007/s12020-016-0984-8. PMID: 27189147

Diagnosis

Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome.
He X, Findling JW, Auchus RJ
Pituitary 2022 Jun;25(3):393-403. Epub 2022 Apr 26 doi: 10.1007/s11102-022-01218-y. PMID: 35471718Free PMC Article
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK; LINC 3 investigators
Lancet Diabetes Endocrinol 2020 Sep;8(9):748-761. Epub 2020 Jul 27 doi: 10.1016/S2213-8587(20)30240-0. PMID: 32730798
Mortality in Patients with Endogenous Cushing's Syndrome.
Javanmard P, Duan D, Geer EB
Endocrinol Metab Clin North Am 2018 Jun;47(2):313-333. doi: 10.1016/j.ecl.2018.02.005. PMID: 29754634
Cushing's disease.
Tritos NA, Biller BM
Handb Clin Neurol 2014;124:221-34. doi: 10.1016/B978-0-444-59602-4.00015-0. PMID: 25248590
Cushing's disease.
De Martin M, Pecori Giraldi F, Cavagnini F
Pituitary 2006;9(4):279-87. doi: 10.1007/s11102-006-0407-6. PMID: 17077950

Therapy

Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
Perosevic M, Tritos NA
Drug Des Devel Ther 2023;17:1303-1312. Epub 2023 Apr 27 doi: 10.2147/DDDT.S315359. PMID: 37143705Free PMC Article
Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome.
He X, Findling JW, Auchus RJ
Pituitary 2022 Jun;25(3):393-403. Epub 2022 Apr 26 doi: 10.1007/s11102-022-01218-y. PMID: 35471718Free PMC Article
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK; LINC 3 investigators
Lancet Diabetes Endocrinol 2020 Sep;8(9):748-761. Epub 2020 Jul 27 doi: 10.1016/S2213-8587(20)30240-0. PMID: 32730798
Medical Management of Cushing's Syndrome: Current and Emerging Treatments.
Hinojosa-Amaya JM, Cuevas-Ramos D, Fleseriu M
Drugs 2019 Jun;79(9):935-956. doi: 10.1007/s40265-019-01128-7. PMID: 31098899
Cushing's disease.
Tritos NA, Biller BM
Handb Clin Neurol 2014;124:221-34. doi: 10.1016/B978-0-444-59602-4.00015-0. PMID: 25248590

Prognosis

Paediatric Cushing syndrome: a prospective, multisite, observational cohort study.
Tatsi C, Kamilaris C, Keil M, Saidkhodjaeva L, Faucz FR, Chittiboina P, Stratakis CA
Lancet Child Adolesc Health 2024 Jan;8(1):51-62. doi: 10.1016/S2352-4642(23)00264-X. PMID: 38097317
Recurrent Cushing's Disease in Adults: Predictors and Long-Term Follow-Up.
Ünal M, Selek A, Sözen M, Gezer E, Köksalan D, Canturk Z, Cetinarslan B, Çabuk B, Anık I, Ceylan S
Horm Metab Res 2023 Aug;55(8):520-527. Epub 2023 Apr 4 doi: 10.1055/a-2047-6017. PMID: 37015254
Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome.
He X, Findling JW, Auchus RJ
Pituitary 2022 Jun;25(3):393-403. Epub 2022 Apr 26 doi: 10.1007/s11102-022-01218-y. PMID: 35471718Free PMC Article
Adrenally Directed Medical Therapies for Cushing Syndrome.
Tritos NA
J Clin Endocrinol Metab 2021 Jan 1;106(1):16-25. doi: 10.1210/clinem/dgaa778. PMID: 33118025
Cushing's disease.
De Martin M, Pecori Giraldi F, Cavagnini F
Pituitary 2006;9(4):279-87. doi: 10.1007/s11102-006-0407-6. PMID: 17077950

Clinical prediction guides

Paediatric Cushing syndrome: a prospective, multisite, observational cohort study.
Tatsi C, Kamilaris C, Keil M, Saidkhodjaeva L, Faucz FR, Chittiboina P, Stratakis CA
Lancet Child Adolesc Health 2024 Jan;8(1):51-62. doi: 10.1016/S2352-4642(23)00264-X. PMID: 38097317
Recurrent Cushing's Disease in Adults: Predictors and Long-Term Follow-Up.
Ünal M, Selek A, Sözen M, Gezer E, Köksalan D, Canturk Z, Cetinarslan B, Çabuk B, Anık I, Ceylan S
Horm Metab Res 2023 Aug;55(8):520-527. Epub 2023 Apr 4 doi: 10.1055/a-2047-6017. PMID: 37015254
Adrenocorticotropic hormone levels before treatment predict recurrence of Cushing's disease.
Kuo CH, Shih SR, Li HY, Chen SC, Hung PJ, Tseng FY, Chang TC
J Formos Med Assoc 2017 Jun;116(6):441-447. Epub 2016 Oct 28 doi: 10.1016/j.jfma.2016.08.008. PMID: 28029519
Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978).
Bertagna C, Orth DN
Am J Med 1981 Nov;71(5):855-75. doi: 10.1016/0002-9343(81)90384-3. PMID: 6272575

Recent systematic reviews

Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
Fleseriu M, Castinetti F
Pituitary 2016 Dec;19(6):643-653. doi: 10.1007/s11102-016-0742-1. PMID: 27600150Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...